Study Update: Exploring the PROAK Study: Tirbanibulin for Actinic Keratosis

The Patient-Reported Outcomes in Actinic Keratosis (PROAK) study investigated the effectiveness and safety of tirbanibulin 1% ointment among adults with actinic keratosis (AK) on the face or scalp. Conducted in real-world community practices across the U.S., the study followed 300 patients over 24 weeks, with key assessments at week 8 (W8) and week 24 (W24).

Results showed significant improvements in quality of life, measured by the Skindex-16, at W8, with strong satisfaction reported by both clinicians and patients at W24 (mean scores of 74.9 and 72.0, respectively). By W24, 83.6% of clinicians and 78.5% of patients noted overall skin appearance improvements. The Investigator Global Assessment (IGA) indicated that 71.9% of patients achieved treatment success at W24, maintaining a similar rate from W8.

While about 5% of patients experienced adverse events, serious reactions were rare, with mild to moderate local skin reactions like erythema and scaling reported most frequently. Overall, tirbanibulin proved effective for managing AK lesions, enhancing quality of life, and demonstrating a favorable safety profile. Both patients and clinicians reported high treatment satisfaction, underscoring the ointment’s positive impact on patient care. To learn more about tirbanibulin and the PROAK Study, click here.

Elevate-Derm Alliance Editorial Committee